TFFP
Income statement / Annual
Last year (2023), TFF Pharmaceuticals, Inc.'s total revenue was $733.87 K,
and the percentage change from the previous year is not available.
In 2023, TFF Pharmaceuticals, Inc.'s net income was -$21.24 M.
See TFF Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$733.87 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$502.48 K
|
$388.22 K
|
$111.45 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$231.39 K
|
-$388.22 K
|
-$111.45 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.32
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$11.56 M
|
$18.50 M
|
$21.30 M
|
$10.68 M
|
$8.82 M
|
$848.81 K
|
$0.00
|
$229.26 K
|
| General & Administrative Expenses |
$10.57 M
|
$13.80 M
|
$10.57 M
|
$8.01 M
|
$3.17 M
|
$0.00
|
$178.61 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.57 M
|
$13.80 M
|
$10.57 M
|
$8.01 M
|
$3.17 M
|
$3.05 M
|
$178.61 K
|
$141.11 K
|
| Other Expenses |
$0.00
|
-$495.81 K
|
-$88.16 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$22.13 M
|
$31.80 M
|
$31.79 M
|
$18.69 M
|
$11.99 M
|
$3.90 M
|
$178.61 K
|
$370.37 K
|
| Cost And Expenses |
$22.63 M
|
$31.80 M
|
$31.79 M
|
$18.69 M
|
$11.99 M
|
$3.90 M
|
$178.61 K
|
$370.37 K
|
| Interest Income |
$0.00
|
$26.73 K
|
$51.23 K
|
$126.42 K
|
$117.33 K
|
$55.96 K
|
$0.00
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$502.48 K
|
$388.22 K
|
$111.45 K
|
$206.30 K
|
$171.86 K
|
$0.00
|
$52.52 K
|
$0.00
|
| EBITDA |
-$20.74 M |
-$31.41 M |
-$30.93 M |
-$18.69 M |
-$11.99 M |
-$3.90 M |
-$178.61 K |
-$370.37 K |
| EBITDA Ratio |
-28.26
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-29.83
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$651.43 K
|
$26.73 K
|
$747.95 K
|
$126.42 K
|
$117.33 K
|
$55.96 K
|
$0.00
|
$0.00
|
| Income Before Tax |
-$21.24 M
|
-$31.77 M
|
-$31.04 M
|
-$18.57 M
|
-$11.87 M
|
-$3.84 M
|
-$178.61 K
|
-$370.37 K
|
| Income Before Tax Ratio |
-28.95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$21.24 M
|
-$31.77 M
|
-$30.99 M
|
-$18.44 M
|
-$11.75 M
|
-$3.84 M
|
-$178.61 K
|
-$370.37 K
|
| Net Income Ratio |
-28.95
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-11.85 |
-26.49 |
-31.21 |
-22.57 |
-42.55 |
-5.21 |
-0.01 |
-0.5 |
| EPS Diluted |
-11.85 |
-26.49 |
-31.21 |
-22.57 |
-42.55 |
-5.21 |
-0.01 |
-0.5 |
| Weighted Average Shares Out |
$1.79 M
|
$1.20 M
|
$992.84 K
|
$817.01 K
|
$276.20 K
|
$738.04 K
|
$17.83 M
|
$738.04 K
|
| Weighted Average Shares Out Diluted |
$1.79 M
|
$1.20 M
|
$992.84 K
|
$817.01 K
|
$276.20 K
|
$738.04 K
|
$17.83 M
|
$738.04 K
|
| Link |
|
|
|
|
|
|
|
|
